Listed

Psyence Biomedical LTD.: Form 20-F for the period ended Mar 31, 2024

Filed with the SEC on Jul 29, 2024 and accepted by EDGAR at Jul 26, 2024, 21:35 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Net income12 months2023-04-01 to 2024-03-31−$51.2mifrs-full:ProfitLoss
Diluted EPS12 months2023-04-01 to 2024-03-31−$7.82ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-04-01 to 2024-03-31−$7.82ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-04-01 to 2024-03-31−$2.9mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-04-01 to 2024-03-31$5.7kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2024-03-31$733.2kifrs-full:CashAndCashEquivalents
Current assetsAt period end2024-03-31$1.1mifrs-full:CurrentAssets
Total assetsAt period end2024-03-31$1.1mifrs-full:Assets
Total liabilitiesAt period end2024-03-31$12.1mifrs-full:Liabilities
Shareholders' equityAt period end2024-03-31−$11.0mifrs-full:Equity
Shares outstandingAt period end2024-03-3113,390,659 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001410578-24-001112. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.